Wells Fargo raises Xencor stock price target on kidney cancer data
Wells Fargo raised its price target for Xencor (NASDAQ:XNCR) to $44 from $30, citing positive kidney cancer trial data. The stock has gained 105% over the past year and trades at $29.18. Analysts highlight potential for further gains through 2026. Other analysts, including RBC and Truist, also increased their price targets.
How this was made
The 30-second read
Why it matters
The fresh efficacy numbers (45% confirmed overall response) drove multiple analysts to raise targets, suggesting a catalyst‑driven price move.
Market read
New trial data and analyst upgrades create a short‑term bullish bias for Xencor (XNCR).
What to watch
Potential safety signals or competitive trial data from rival firms could temper the rally.
Background
The article summarizes analyst price‑target revisions following new clinical data for Xencor's XmAb819 therapy presented at the ESMO conference.
Ticker impact
Wells Fargo raised its price target on Xencor to $44 after positive Phase 3 data for XmAb819 in renal cell carcinoma presented at ESMO.
likely upward pressure as the market prices in the upgraded target and trial optimism
Multiple sell‑side houses lifted targets on the same fresh data, indicating consensus bullish view.
Market effects
Positive biotech trial results may lift peer oncology stocks and the broader biotech sector.
U.S. biotech market gains as investors re‑price pipeline risk.
Limited to biotech investors; no broad macro effect.
Counterpoint
If the Phase 3 data fails to translate into regulatory approval, the upgraded targets could be premature.
Key entities
- AnalystWells Fargo
Raised Xencor target to $44, Overweight
- AnalystRBC Capital
Raised target to $43
- AnalystTruist Securities
Raised target to $29
